Actively Recruiting
Effects of Minocycline on Patients With Ischemic Stroke Undergoing Intravenous Thrombectomy
Led by Xijing Hospital · Updated on 2025-07-24
180
Participants Needed
1
Research Sites
149 weeks
Total Duration
On this page
Sponsors
X
Xijing Hospital
Lead Sponsor
X
Xi'an No.3 Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
Minocycline is the second generation of tetracycline. Because of its lipophilicity, it has high penetrance of blood-brain barrier. Animal model studies have shown that minocycline can reduce cerebral damage after ischemic stroke, and its mechanism involves multiple molecular pathways, such as antioxidant, anti-inflammatory, anti apoptotic pathways, and protection of blood-brain barrier. Clinical studies have also shown that minocycline can significantly improve 3-month National Institute of Health Stroke Scale (NIHSS) and modified Rankin Scale (mRS) of patients with ischemic stroke, indicating that minocycline is a potential neuroprotective drug. Minocycline is believed to protect the blood-brain barrier, thereby reducing the ischemia-reperfusion injury caused by mechanical thrombectomy. However, whether minocycline can become a synergistic treatment method of mechanical thrombectomy, there is no clinical research in this area at present. Therefore, investigators carry out the study on the effect of minocycline in patients with acute anterior circulation ischemic stroke after mechanical thrombectomy, and plan to enroll 180 patients. To explore the safety and effectiveness of minocycline in patients with acute ischemic stroke after thrombectomy.
CONDITIONS
Official Title
Effects of Minocycline on Patients With Ischemic Stroke Undergoing Intravenous Thrombectomy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with acute cerebral infarction of anterior circulation accompanied by large vessel occlusion
- Age 18 to 85 years old
- Stroke onset time within 6 hours or within 24 hours suitable for mechanical thrombectomy as determined by multimodal imaging
- For onset between 6 and 24 hours, infarct volume less than one-third of the MCA blood supply area by DWI
- For onset within 6 hours, ASPECTS score 6 or higher
- Preoperative NIHSS score between 6 and 30 points
- Signed informed consent form
You will not qualify if you...
- Contraindications for mechanical thrombectomy
- No revascularization therapy performed or TICI score after therapy less than 2b
- Other major central nervous system diseases such as brain injury, brain tumor, or multiple sclerosis
- Evidence of bacterial endocarditis, aortic dissection, arteritis, or venous cerebral infarction
- Renal insufficiency or hepatic insufficiency with specified lab thresholds
- History of congestive heart failure or myocardial infarction within 6 months
- Life-threatening or severe diseases affecting follow-up or evaluation
- Pre-existing neurological deficits or history of dementia
- Infectious diseases requiring antibiotic treatment before the stroke
- Allergy to tetracyclines or inability to take minocycline
- Minocycline could not be given within 1 hour after recanalization
- Pregnant patients
- Participation in another clinical trial within 30 days before enrollment
- Refusal to sign informed consent form
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Xijing Hospital
Xi'an, China
Actively Recruiting
Research Team
W
Wen Jiang, Ph.D
CONTACT
F
Fang Yang, Ph.D
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here